Q-omics provides the consensus-scored C2CD2L profile across patient tissues and cancer cell-line models. C2CD2L expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, C2CD2L is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, C2CD2L protein abundance shows 24,507 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KICH, and GBM as cancer lineages where C2CD2L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C2CD2L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C2CD2L survival associations across molecular data types. C2CD2L RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C2CD2L RNA expression–survival associations across cancer types. High C2CD2L expression shows unfavorable associations in ACC, KICH, LUSC, KIRC and LIHC, but favorable associations in HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for C2CD2L RNA expression.
This table summarizes C2CD2L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for C2CD2L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C2CD2L shows lower tumor expression in KICH, COAD, LUSC and KIRC and higher tumor expression in LIHC and BRCA. The KICH box plot shows higher C2CD2L RNA expression in normal versus tumor tissue (log2 FC = −0.937, t-test p < 0.001).
This table shows molecular features associated with C2CD2L in patient tissues and cancer cell lines. In patient samples, C2CD2L shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, C2CD2L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BREAST.
